9,720 Shares in Masimo Co. (NASDAQ:MASI) Acquired by Lecap Asset Management Ltd.

Lecap Asset Management Ltd. acquired a new stake in Masimo Co. (NASDAQ:MASI) during the 4th quarter, Holdings Channel reports. The institutional investor acquired 9,720 shares of the medical equipment provider’s stock, valued at approximately $1,607,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of MASI. FMR LLC grew its holdings in shares of Masimo by 41.2% in the third quarter. FMR LLC now owns 6,756,618 shares of the medical equipment provider’s stock worth $900,860,000 after purchasing an additional 1,970,883 shares during the last quarter. Westfield Capital Management Co. LP boosted its position in Masimo by 23.2% in the 3rd quarter. Westfield Capital Management Co. LP now owns 1,394,056 shares of the medical equipment provider’s stock valued at $185,869,000 after buying an additional 262,370 shares during the period. Assenagon Asset Management S.A. grew its stake in Masimo by 916.1% in the 4th quarter. Assenagon Asset Management S.A. now owns 216,051 shares of the medical equipment provider’s stock worth $35,713,000 after acquiring an additional 194,788 shares in the last quarter. Clearline Capital LP purchased a new position in shares of Masimo during the third quarter worth approximately $21,337,000. Finally, ING Groep NV raised its stake in shares of Masimo by 143.3% during the third quarter. ING Groep NV now owns 240,900 shares of the medical equipment provider’s stock valued at $32,119,000 after acquiring an additional 141,900 shares in the last quarter. Hedge funds and other institutional investors own 85.96% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on MASI. Piper Sandler increased their price objective on Masimo from $180.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 18th. Raymond James raised their price target on Masimo from $170.00 to $194.00 and gave the company an “outperform” rating in a research note on Friday, December 27th. Wells Fargo & Company upped their price objective on shares of Masimo from $171.00 to $193.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 11th. Stifel Nicolaus reissued a “buy” rating and set a $190.00 target price (up previously from $170.00) on shares of Masimo in a research report on Friday, November 22nd. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a research report on Wednesday, January 22nd. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $191.40.

Masimo Price Performance

MASI opened at $180.02 on Friday. The firm has a market capitalization of $9.64 billion, a PE ratio of 124.15 and a beta of 1.02. The business’s 50-day moving average is $171.38 and its two-hundred day moving average is $146.13. Masimo Co. has a 1 year low of $101.61 and a 1 year high of $183.14. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11.

Masimo (NASDAQ:MASI) last issued its quarterly earnings data on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.84 by $0.14. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The firm had revenue of $504.60 million for the quarter, compared to the consensus estimate of $502.87 million. During the same quarter in the previous year, the firm earned $0.63 EPS. The company’s quarterly revenue was up 5.4% compared to the same quarter last year. Research analysts anticipate that Masimo Co. will post 4.1 earnings per share for the current fiscal year.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.